Oncology ICU summit
The Oncology ICU Summit is a hybrid continuing medical education activity designed to address the growing complexity of critical care in patients with cancer. Delivered over two half-days in both in-person and virtual formats, the program brings together faculty from the Cleveland Clinic Medical Oncology ICU and nationally and internationally recognized experts in oncology, critical care, pulmonary medicine, infectious diseases, and related specialties.
This activity provides a case-based review of contemporary oncologic emergencies, with particular emphasis on complications associated with novel anticancer therapies such as targeted agents, immune checkpoint inhibitors, antibody-drug conjugates, bispecific antibodies, and cellular therapies such as CAR T-cell therapy. These therapies have transformed cancer care, but they also introduce unique and potentially life-threatening toxicities that differ from those of conventional chemotherapy. Clinicians across all practice settings are increasingly encountering these complex presentations that require early recognition and specific treatment to ensure best patient outcomes.
Using real-world cases and expert-led discussion, the summit will highlight the clinical presentation, differential diagnosis, and management of treatment-related toxicities and other oncologic emergencies in critically ill patients. The program emphasizes practical, evidence-based approaches to early recognition, diagnostic evaluation, timely and multidisciplinary management. This Oncology ICU Summit is intended to strengthen clinician preparedness for caring for critically ill patients with cancer in an era of rapidly evolving therapeutics.
By Participating, You Will Be Able To:
Upon completion of this activity, learners will be able to:
- Describe the mechanisms and toxicity profiles of major classes of novel anticancer therapies, including targeted agents, immune checkpoint inhibitors, antibody-drug conjugates, bispecific antibodies, and cellular therapies.
- Apply evidence-based approaches to the evaluation and management of acute respiratory failure in patients with cancer.
- Differentiate sepsis, disease progression, and treatment-related toxicities in critically ill oncology patients to support timely diagnosis and management.
- Recognize and manage key toxicities associated with CAR T-cell therapy, including cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis.
- Incorporate evolving evidence on treatment response, prognosis, and toxicity into multidisciplinary communication, shared decision-making, and care planning.
- Identify practical strategies for effective, patient centered interdisciplinary care delivery for critical care for oncology patients across practice settings.
Who Should Attend?
Intensivists, hospitalists, emergency physicians, community oncologists, advanced practice providers